Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
Business Wire India– Chronic kidney disease (CKD) affects 850 million people worldwide,1 47 million in the EU,2 doubles a person’s risk for hospitalization,3 and is a leading cause of death2…